Propanc Biopharma, an Australian clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors (pancreatic, ovarian and colorectal cancers), entered into a research collaboration agreement with the University of Jaén (Spain), for the provision of research services and scientific technical advice for drug discovery program.
Propanc Biopharma developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body by targeting and eradicating cancer stem cells.
PRP is a solution for intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Progressing towards a first-in-human study, PRP seeks to prevent recurrence and metastasis from solid tumors by targeting and eradicating cancer stem cells.
The goal for the collaboration program is to synthesize and develop a backup clinical compound to the Company’s lead product candidate, PRP. The development of the backup compound will be used for treating patients with limited therapeutic options for the treatment of solid tumors.
The specific objectives for the collaboration include:
- The identification of a suitable backup clinical compound to PRP;
- The validation of the anti-carcinogenic properties of the new drug candidate through in vitro testing;
- The validation of the anti-carcinogenic properties of the new drug candidate through in vivo testing;
- The production of the new synthetic drug candidate in compliance with FDA’s current good manufacturing practice (cGMP) conditions, in order for it to be used in human trials.
Dr. Macarena Perán Quesada, Professor at the University of Jaén, will be in charge of management and coordination of the working team and will be the scientific consultant in charge of the project run by the University of Jaén. Dr. Perán is the lead author of several scientific papers jointly published with the Propanc Biopharma regarding the anti-cancer and anti-tumor effects of PRP, as well as a co-inventor of several patents in its intellectual property portfolio, including the discovery of PRP as a targeted, cancer stem cell therapy.
The University of Jaén is repeatedly in the top 4% of universities worldwide, according to the Ranking Center for World University Rankings (CWUR). Also, it is among the 75 best universities in the world, according to Academic Ranking of World Universities (ARWU) 2017.